FilingSEC EDGAR8-K
Moleculin Biotech Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin
· SEC accepted
Filing content
Moleculin Biotech announced the publication of a peer-reviewed analysis in Frontiers in Cardiovascular Medicine, reporting no evidence of cardiotoxicity in 90 patients treated with Annamycin.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…